Level C· Early human research exploring benefitsProspective StudyPubMed

Inflammatory Response to Menstrual Fluid Does Not Induce Fibrotic Morphogenesis Program in Human Endometrial Stromal Cells.

Eremichev R., Khandokhin M., Alexandrushkina N., Radnaeva A., Nimiritsky P., Tkachuk V.

Prospective Study on Chronic Wound, Scar, Chronic Inflammation, published in Cells Tissues Organs (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cells Tissues Organs (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41553962
DOI
10.1159/000550511

Abstract (original English)

Human endometrium is one of peculiar tissues capable of scarless regeneration after injury during every menstrual cycle, birth, or surgery. However, it is disputable whether this feature should be attributed to specific regulatory factors of wound environment and menstrual fluid (MF) or to tissue-specific properties of endometrial mesenchymal stromal cells (eMSCs), which are pivotal participants of wound healing. We aimed to elucidate the role of eMSC tissue specificity in wound healing. We evaluated changes of eMSC transcriptomic profile in response to MF and their potency to granulation tissue formation in vitro in comparison with those of stromal cells from scar-forming organs - dermal and adipose MSC (dMSC and adMSC). We have found that MF contains numerous inflammatory factors and induces a profound inflammatory response in both eMSC and dMSC, but a tissue-specific component was identified in their transcriptome profiles. Furthermore, transcriptomic tissue specificity was stable and present prior to MF treatment as well as after it, so we validated our findings against in vivo single-cell RNA-sequencing data from Human Protein Atlas. Tissue specificity traits were related to embryonic development and morphogenesis, suggesting a putative contribution of "developmental imprinting" in its establishment. Using in vitro models of fibroplasia, angiogenesis, and extracellular mat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansFemaleEndometriumMenstruationInflammationFibrosisMesenchymal Stem CellsMorphogenesisStromal CellsAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research